It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
An experimental drug made by Durham drug developer Chimerix is being administered in Texas to a Liberian man infected with the Ebola virus.
Texas Health Presbyterian Hospital in Dallas on Monday confirmed that Thomas Duncan is receiving the treatment.
“Mr. Duncan remains in critical condition. His condition is stable,” the hospital’s statement said. “He is now receiving an investigational medication, brincidofovir, for Ebola Virus Disease.”
Brincidofovir is made by Chimerix and is being tested for a variety of potent viruses.
Chimerix announced earlier Monday that it would be able to give the drug to Ebola patients as requested by treating physicians. The emergency request was granted by the U.S. Food and Drug Administration’s Emergency Investigational New Drug Applications branch.
Read more here: www.charlotteobserver.com...
I hope he does well as this trial drug seems promising.
edit on 6-10-2014 by marg6043 because: (no reason given)
Chimerix, a 12-year-old drug developer with no products on the market, posted a $10.1 million first quarter loss as the company pushes ahead to win approval for its lead candidate, brincidofovir.
The potentially lifesaving drug recently gained the Durham company international media attention after the family of dying boy mounted a successful social media campaign to obtain the unapproved antiviral for the child on an experimental basis.
Brincidofovir is being developed to prevent fatal virus infections in certain cell transplant patients, the primary focus for Chimerix. The drug is not expected to win regulatory approval for public use until late 2016 at the earliest.
The experimental treatment is also being tested as a potential cure to infections of adenovirus, which causes the common cold in healthy people but can be fatal to patients with compromised immune systems. Brincidofovir attacks potent viruses without the toxic side effects of cidofovir, the primary medication in use today.
The first patient to receive the drug in pilot trial to cure viral infections was Josh Hardy, 8, the four-time cancer survivor whose family lobbied to gain access to brincidofovir. The boy has since been released from the hospital.
Chimerix’s first quarter loss was expected and is comparable to the $9.1 million first quarter loss in 2013.